Spreeha Choudhury and Richard H. Hughes, IV, attorneys in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, co-authored an article in Health Affairs, titled “ACIP’s Upcoming Meningococcal Recommendations: Added Complexity, Reduced Choice.”
Following is an excerpt:
As vaccine innovation has provided increased options for protecting adolescents from invasive meningococcal disease, the Advisory Committee on Immunization Practices (ACIP) has grappled with how to best structure its recommended immunization schedule. In the process, it has prioritized economic considerations and a more rigid recommendation over one that is practically implementable in everyday clinical practice.
While aiming to streamline the meningococcal vaccination schedule, the committee has instead added complexity. As a result, providers are effectively asked to stock three separate vaccine products rather than two. The committee is expected to reevaluate the meningococcal vaccination schedule in 2025, and we believe that it must more fully account for implementation considerations, including provider choice.
People
Services
- Drug and Medical Device Coding, Coverage, and Payment
- Drug and Medical Device Distribution
- Drug Pricing Policy & Reporting
- Health Insurance Exchanges
- Health Policy and Legislation
- Insurance Coverage and Reinsurance Disputes
- Product Marketing and Compliance
- Regulatory Strategy, Product Development, and Product Approvals